| 书目名称 | The New Drug Reimbursement Game |
| 副标题 | A Regulator’s Guide |
| 编辑 | Brita A.K. Pekarsky |
| 视频video | http://file.papertrans.cn/915/914815/914815.mp4 |
| 概述 | Addresses the choice of the decision threshold and the relationship between pharmaceutical innovation, price and future health.Provides a practical introduction to applied game theory.Allows experienc |
| 图书封面 |  |
| 描述 | .This comprehensive text presents a rigorous framework from within which regulators can respond strategically to the claim by the pharmaceutical industry that lower drug prices today lead to a loss for the population’s future health due to less innovation. It starts with a critical review of the empirical evidence of the return to consumers on their ongoing investment into high drug prices in order to increase future innovation. The implicit, critical and unrealistic assumption inherent in these studies is identified, namely that the health budget can be expanded to purchase drugs at higher prices without an opportunity cost, for example, the foregone benefits of alternative investments in health care infrastructure. .Price effectiveness analysis (PEA), is introduced. PEA informs the question of how the innovative surplus from the new drug should be allocated between the manufacturer and the consumer so as to optimise society’s welfare. The method allows the decisions by theregulator and the firm to be analysed jointly by specifying the firm’s production and revenue functions in terms of the clinical innovation of a new drug; the incremental effect used in the summary metric of |
| 出版日期 | Book 2015 |
| 关键词 | Budget constraints; Future innovation and health; Healthcare system; Threshold price for new drug; pharm |
| 版次 | 1 |
| doi | https://doi.org/10.1007/978-3-319-08903-4 |
| isbn_softcover | 978-3-319-34920-6 |
| isbn_ebook | 978-3-319-08903-4 |
| copyright | Springer International Publishing Switzerland 2015 |
|Archiver|手机版|小黑屋|
派博传思国际
( 京公网安备110108008328)
GMT+8, 2025-7-28 07:38
发表于 2025-3-21 19:09:07
